Tag: Endometrial Cancer

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update V2.2024 – #2 EPCAM Updates

The National Comprehensive Cancer Network (NCCN) released updated Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on October 3rd, 2024. In these updated guidelines, NCCN revised information about EPCAM gene (which has usually been lumped together with MSH2) as follows ⤸ You can check out the full guidelines by creating a FREE account …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102224/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #5: ATM Update

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these new guidelines, there were several updates for ATM carriers, including adding colorectal cancer risk as outlined in GENE-A (Page 35) and consideration of pancreatic cancer screening as outlined in PANC-A 1 of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101724_1/

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update V2.2024 = #1 Testing Considerations

The National Comprehensive Cancer Network (NCCN) released updated Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on October 3rd, 2024. In these updated guidelines, NCCN added the following to testing being considered ⤸Personal history of colorectal or endometrial cancer at or older than age 50, and: You can check out the full guidelines …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101524/

ICARE Social Media Post October 2024

NCCN CDH1 Guideline Update

CDH1 gastric cancer risk management options are included in the recently released National Comprehensive Cancer Network (NCCN) Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines. Gastric (stomach) cancer risk management options include ⤸ In certain circumstances, gastrectomy is recommended based on findings at biopsy or endoscopy or other persistent unexplained symptoms. Regardless, a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100924/

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update V2.2024

The National Comprehensive Cancer Network (NCCN) released updated Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on October 3rd, 2024. Updates include ⤸ Added the following to testing being considered: Personal history of colorectal or endometrial cancer at or older than age 50, and: Revised information about EPCAM gene (which has usually been …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100824/

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 5

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. An important update includes the revision of CHEK2 estimated absolute colon cancer risk to “NO INCREASED RISK”; thus, general population screening is appropriate for these individuals. You can check out the full guidelines …

Continue reading

Permanent link to this article: https://inheritedcancer.net/100624-2/

ICARE Newsletter Fall 2024

National Comprehensive Cancer Network (NCCN) Guideline Updates

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer – Released September 11th, 2024 (V1.2025) Check out the full guidelines by creating a FREE account at www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Testing Updates: Gene Updates: Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric Cancer – Released August 8th, 2024 (V1.2024) Check out the full guidelines by creating a FREE account at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-national-comprehensive-cancer-network-nccn-guideline-updates/

ICARE Social Media Post September 2024

NCCN CEG Guideline Update #3: Use of HRT following premature surgical menopause

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include use of hormone replacement treatment following premature surgical menopause from risk-reducing oophorectomy. You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf

Permanent link to this article: https://inheritedcancer.net/poat92524/

ICARE Social Media Post September 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 3

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include gynecologic risk and preventive surgery considerations for MLH1, MSH6, MSH2, and PMS2 carriers. You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf

Permanent link to this article: https://inheritedcancer.net/post91824/

ICARE Social Media Post September 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 2

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include ⤸ You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf

Permanent link to this article: https://inheritedcancer.net/post91424/

ICARE Social Media Post September 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update

The National Comprehensive Cancer Network (NCCN) released the new Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include ⤸• Endometrial cancer recommendations included throughout• Hereditary Diffuse Gastric Cancer section added (HGAST-1)• Gynecologic risk and preventive surgery considerations for those with Lynch Syndrome• Use of hormone replacement treatment following …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post90324/

ICARE Social Media Post June 2023

Inherited Gene Mutation in Those with Multiple Primary Cancers

Among patients with multiple primary cancers, the proportion with inherited cancer gene mutations increased with the number of primary cancers:• 2 cancers: 13.1%• 3 cancers: 15.9%• 4+ cancers: 18.0% Many of the double primaries, such as those of the breast, ovary, colorectum, and endometrium, occurred in women who would already be eligible for genetic testing. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60723/

ICARE Social Media Post May 2023

Lynch Syndrome: Skin Neoplasms

According to a recent study among individuals with Lynch Syndrome: Use the link in bio to learn more! Reference: Zhong et al. J Am Acad Dermatol. 2023;S0190-9622(23)00173-1. PMID: 36773823.

Permanent link to this article: https://inheritedcancer.net/post50623/

ICARE Social Media Post March 2023

New Model: To identify those at high risk for Endometrial (Uterine) Cancer

Did you know endometrial cancer is the 4th most common cancer among females? Currently, clinical practice guidelines do not recommend endometrial cancer screening in the general population. A new risk prediction model was recently developed to identify those at high risk for endometrial (uterine) cancer to determine who could benefit from cancer screenings and risk-reducing …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32623/

ICARE Newsletter Spring 2022 

  BRCA1/2 Oral Contraceptives and Breast Cancer

A new study found that among BRCA1/2 carriers, oral contraceptive use strongly lowered cancer risk over one’s lifetime, even though at first, they raise risks of breast, ovarian, and endometrial cancer.Schrijver et al. J Natl Cancer Inst. 2022 Jan. PMID: 35048954. Social media post February 15th, 2022. Available at:https://tinyurl.com/post21522.

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-brca1-2-oral-contraceptives-and-breast-cancer/

ICARE Social Media Post February 2022

BRCA1/2 Cancer Risks: Oral Contraceptives

A new study found that among BRCA1/2 carriers oral contraceptive use strongly decreases lifetime cancer risk, despite an 𝗶𝗻𝗶𝘁𝗶𝗮𝗹 increase in breast, ovarian, and endometrial cancer risk. Read the full article to learn more!https://pubmed.ncbi.nlm.nih.gov/35048954/Reference: Schrijver et al. J Natl Cancer Inst. 2022 Jan 20;djac004. PMID: 35048954

Permanent link to this article: https://inheritedcancer.net/post21522/

ICARE Newsletter Summer 2020

Treatment Advances Among Those with Lynch Syndrome

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Lynch Syndrome:  Colorectal Cancer: Among patients with MSI-H or MMR-deficient colorectal cancers (frequently seen among those with Lynch syndrome), pembrolizumab …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nls2020/

ICARE Social Media Post January 2020

Advances in Treatment for Lynch Syndrome-Related Endometrial Cancer

A recent phase II study showed increased response to an immunotherapy drug (avelumab), in women with endometrial cancer with mismatch repair deficiency. Among women with Lynch Syndrome, the risk for endometrial cancer (which often has mismatch repair deficiency) is raised. This new study shows promising treatment options for women with endometrial cancer and Lynch syndrome …

Continue reading

Permanent link to this article: https://inheritedcancer.net/13020/

ICARE Newsletter Summer 2018

Refining Cancer Risks Among Individuals with Lynch Syndrome

Over the past year, multiple studies have refined risks and types of cancer among individuals with Lynch syndrome. Through a Scandinavian study, risks for 13 types of cancer (with colorectal cancers being excluded), were reported to be elevated with differences related to gender, age, and the gene in which mutation was present. Incidence rates of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2018/

ICARE Newsletter Summer 2016

What Are the Endometrial Cancer Risks Among BRCA Carriers?

Although BRCA mutations confer increased risk for ovarian, fallopian tube, and primary peritoneal cancer, there have been limited and conflicting risks reported for endometrial cancer. Consequently, current practice guidelines only recommend the removal of the fallopian tubes and ovaries as a risk-reducing option for BRCA carriers.1 Specifically, through a prospective study of 4500 women with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/9nls2016/

ICARE Newsletter Summer 2016

Risk of Second Cancers Among Those with PTEN Mutations

A recently published study to evaluate the risk of second cancers among PTEN mutation carriers showed that women with breast cancer had a 10-year second breast cancer cumulative risk of almost 30%. Overall, the risk of second primary cancers was almost 8-fold that of the general population, primarily due to the higher risks of cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/8nls2016/

ICARE Newsletter Summer 2014

Ask the Expert

The following question was addressed by Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at Women’s College Research Institute in Toronto, Canada.  Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Over the course of his career, he has profoundly shaped …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2014/